Health Care • Biotechnology: Pharmaceutical Preparations
$31.26 ▼ -0.81
(-2.53%)
MKT CAP: $4.03B • VOL: 1.51M
52W L $19 52W H $33
ARQT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $376.1M | $196.5M | $59.6M |
| YoY Revenue Growth % | +91.3% | +229.7% | — |
| Gross Profit | $339.4M | $177.4M | — |
| Gross Margin % | 90.2% | 90.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$12.2M | -$128.4M | -$241.1M |
| Operating Margin % | -3.3% | -65.3% | -404.5% |
| Net Income (GAAP) | -$16.1M | -$140.0M | -$262.1M |
| EBITDA (Normalized) | -$11.7M | -$128.3M | -$239.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.6M | -$112.2M | -$247.1M |
| Capital Expenditures (CapEx) | $686.0K | $143.0K | $2.7M |
| Free Cash Flow (FCF) | -$6.3M | -$112.3M | -$249.7M |
| FCF Margin % | -1.7% | -57.1% | -419.0% |
| Return on Invested Capital (ROIC %) | -3.8% | -45.0% | -14.3% |
| Cash & Short-Term Equivalents | $42.9M | $71.3M | — |
| Total Debt (Short + Long Term) | $108.0M | $107.2M | $517.2M |
| Total Stockholders' Equity | $189.5M | $157.5M | $1.06B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ARQT.